Publications by authors named "Jose Ramon Alberto Alonso"
Health-related quality of life determinants in Spanish children with eosinophilic esophagitis.
J Pediatr Gastroenterol Nutr
December 2024
Objectives: To study the health-related quality of life (HRQoL) and its possible determinant factors in Spanish children with eosinophilic esophagitis (EoE) and their parents.
Methods: Multicenter observational cross-sectional study. The Spanish version of the Pediatric Quality of Life Eosinophilic Esophagitis Module was filled out by EoE patients aged 8-18 and their parents.
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP.
J Clin Med
July 2023
(1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation is not yet established in all inflammatory bowel disease (IBD) units. The aim of the study was to evaluate the impact of transition on IBD outcomes. (2) Methods: Multicentre, retrospective and observational study of IBD paediatric patients transferred to an adult IBD unit between 2017-2020.
View Article and Find Full Text PDFCorrection to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study.
Eur J Pediatr
September 2021
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Eur J Pediatr
September 2021
Article Synopsis
- Vedolizumab is a monoclonal antibody that targets integrin α4β7 on T-cells, preventing their migration to the gastrointestinal tract, and has been primarily used to treat inflammatory bowel disease in adults, though data on its use in children is limited.
- A study was conducted on 42 pediatric patients with inflammatory bowel disease who did not respond to previous anti-TNF therapies, evaluating the effectiveness and safety of vedolizumab for inducing and maintaining clinical remission.
- Results showed that at 14 weeks, 69% of patients responded to treatment and 52.4% achieved remission, with the response rates remaining high at 30 weeks, and most patients who achieved remission at week 14 maintained it at week